A Phase 1 interventional study of KPT-330 in Hematological Malignancies, sponsored by Karyopharm Therapeutics Inc. Completed at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Karyopharm Therapeutics Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.
Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 58th largest by enrollment of the 658 interventional ones that give a count, is one of 30 that started in 2012, is one of 195 in phase 1, and was the 216th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Orum Therapeutics USA, Inc. · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
821 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 276 · Phase 2 280 · Phase 3 43 · Phase 4 9
First in 1989; this study’s year is marked. 30 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 286 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 40 across the 658 interventional studies, 150 across the 157 observational. Of the 497 that completed or were terminated, 208 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 821 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 1 study filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
90 of the studies in Hematologic Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT04188418Phase 3M.D. Anderson Cancer CenterFentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | 2027-08-31 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT02203903Catherine BollardMulti-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | 2026-11-30 |
Add all 90 to your calendar (.ics) → With an account.
Among the 821 studies in Hematologic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the blood (pharmacokinetics or PK), to examine the effects of KCP-330 on the body (pharmacodynamics or PDn) and to obtain information on its effectiveness in treating cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KPT-330
Also known as: Selinexor
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product during the course of a study and which does not necessarily have to have a causal relationship with this treatment. An Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. TEAEs are any untoward medical incidence in a participant during administered study treatment, whether or not these events were related to study treatment.
Time frame: From first dose of study drug administration to end of treatment (up to 27 months)
Recommended Phase 2 Dose (RP2D) of Selinexor
Recommended Phase 2 dose was determined by maximum tolerated dose (MTD). MTD was defined as the next lower dose level below the one in which \> 1 of 3 participants or ≥ 2 of 6 participants experienced dose-limiting toxicity (DLT), provided that that dose level is ≤25% lower than the highest dose tested. If the projected MTD was \>25% lower than the highest dose tested, then an additional cohort of ≥3 participants were added at a dose that was intermediate between the intolerable dose and the next lower dose.
Time frame: From first dose of study drug administration to end of treatment (up to 27 months)
Maximum Observed Plasma Concentration (Cmax) of Selinexor
Cmax was defined as the maximum observed concentration, taken directly from the plasma concentration.
Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2
Time to Maximum Observed Concentration (Tmax) of Selinexor
Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.
Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2
Average Concentration From Time 0 to 24 Hours (Cavg0-24h) of Selinexor
Cavg0-24h was defined as average concentration from time 0 to 24 hours.
Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2
Area Under the Concentration-Time Curve From Time 0 to t (AUC0-t) of Selinexor
AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.
Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2
Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selinexor
AUC0-inf was defined as the area under the concentration-time curve from time zero to infinity (extrapolated).
Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2
Apparent Volume of Distribution Uncorrected for Fraction Absorbed (Vd/F) of Selinexor
Apparent volume of distribution was calculated as Dose/ (kel \*AUC0-inf), uncorrected for fraction absorbed, reported normalized by participant body weight (kilogram \[kg\]).
Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2
Apparent Total Body Clearance, Uncorrected for Fraction Absorbed (Cl/F) of Selinexor
Cl/F was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed, reported normalized by participant body weight (kg).
Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2
Terminal Half-Life (t½) of Selinexor
t½ was, calculated as ln(2)/kel, where kel is elimination rate constant, calculated using linear regression on the terminal portion of the log-linear concentration versus time curve.
Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2
Number of Participants With Overall Response of Selinexor
Objective response for each malignancy was defined using the disease response criteria by malignancy; For NHL (including DLBCL, PTCL, and CTCL), objective response included complete response (CR) and partial response (PR). For MM, objective response included stringent complete response (sCR), CR, very good partial response (VGPR), and PR. For WM, objective response included CR, VGPR, and PR. For CLL, ALL, and AML, objective response included complete remission and Partial remission. For CML, objective response includes complete cytogenic response, and complete hematologic response (CHR).
Time frame: From first dose of study drug administration to end of treatment (up to 27 months)
Duration of Response
Duration of response was defined as the time from the first occurrence of objective response to first documented evidence of disease recurrence or progression. Participants without evidence of progression were censored at time of last evaluable disease assessment. Objective response was defined as any response of partial response/remission or better for all malignancies; for AML, a response of morphologic leukemia-free state is also included for ORR. Duration of response was calculated by Kaplan-Meier method.
Time frame: From first dose of study drug administration to end of treatment (up to 27 months)
Progression-free Survival
Progression-free survival (PFS) was calculated from the date of first dose of study drug to first documented evidence of disease recurrence or progression or death due to any cause. Participants who were last known to be alive and without evidence of progression were censored at time of last evaluable disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, participants were censored at the time of last evaluable disease assessment prior to the missed assessment.
Time frame: Cycle 1 Day 1 to End of Treatment (up to 27 months)
Duration of at Least Stable Disease
Duration of at least stable disease was defined as the time from the date of first dose of study drug to first documented evidence of disease recurrence or progression. Participants without evidence of progression were censored at time of last evaluable disease assessment.
Time frame: Cycle 1 Day 1 to End of Treatment (up to 27 months)
Overall Survival
Overall Survival was calculated from the date of first dose of study drug to date of death due to any cause. Participants who were last known to be alive were censored at time of last contact. Overall survival was calculated by Kaplan-Meier method.
Time frame: Cycle 1 Day 1 to End of Treatment (up to 27 months)
The study was conducted at 12 sites in United States, Canada and Europe between 23 July 2012 (first participant treated) and 13 October 2015 (last participant completed).
| Milestone | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| Started | 58 | 27 | 81 | 95 | 24 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 58 | 27 | 81 | 95 | 24 |
| Withdrew: Need of treatment not allowed per protocol | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 4 | 2 | 8 | 10 | 3 |
| Withdrew: Investigator discretion | 2 | 4 | 4 | 8 | 0 |
| Withdrew: Other treatments became available | 1 | 1 | 0 | 0 | 2 |
| Withdrew: Intercurrent illness | 1 | 0 | 0 | 3 | 0 |
| Withdrew: Non-compliance with study procedures | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Consent withdrawn by participant | 9 | 4 | 24 | 14 | 4 |
| Withdrew: Disease progression | 38 | 13 | 37 | 57 | 9 |
| Withdrew: Incidence or severity of adverse events | 3 | 3 | 7 | 2 | 6 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product during the course of a study and which does not necessarily have to have a causal relationship with this treatment. An Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. TEAEs are any untoward medical incidence in a participant during administered study treatment, whether or not these events were related to study treatment.
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| At Least One TEAE | 58 | 27 | 81 | 95 | 24 |
| At Least One Serious TEAE | 33 | 7 | 52 | 73 | 13 |
Recommended Phase 2 dose was determined by maximum tolerated dose (MTD). MTD was defined as the next lower dose level below the one in which \> 1 of 3 participants or ≥ 2 of 6 participants experienced dose-limiting toxicity (DLT), provided that that dose level is ≤25% lower than the highest dose tested. If the projected MTD was \>25% lower than the highest dose tested, then an additional cohort of ≥3 participants were added at a dose that was intermediate between the intolerable dose and the next lower dose.
| milligram per square meter (mg/m^2) | Advanced Hematological Malignancies. |
|---|---|
| Recommended Phase 2 Dose (RP2D) of Selinexor | 35 |
Cmax was defined as the maximum observed concentration, taken directly from the plasma concentration.
| nanogram per milliliter (ng/mL) | Selinexor (3 mg/m^2) | Selinexor (6 mg/m^2) | Selinexor (12 mg/m^2) | Selinexor (16.8 mg/m^2) | Selinexor (23 mg/m^2) | Selinexor (30 mg/m^2) | Selinexor (35 mg/m^2) | Selinexor (40 mg/m^2) | Selinexor (46 mg/m^2) | Selinexor (55 mg/m^2) | Selinexor (60 mg/m^2) | Selinexor (70 mg/m^2) | Selinexor (80 mg/m^2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Selinexor | 49.0 ± NA | 50.0 ± 61.1 | 149 ± 37.6 | 205 ± 46.8 | 262 ± 37.5 | 387 ± 37.1 | 407 ± 44.4 | 416 ± 36.6 | 670 ± 18.5 | 583 ± 41.4 | 668 ± 33.2 | 800 ± 32.4 | 1068 ± 49.3 |
Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.
| hour | Selinexor (3 mg/m^2) | Selinexor (6 mg/m^2) | Selinexor (12 mg/m^2) | Selinexor (16.8 mg/m^2) | Selinexor (23 mg/m^2) | Selinexor (30 mg/m^2) | Selinexor (35 mg/m^2) | Selinexor (40 mg/m^2) | Selinexor (46 mg/m^2) | Selinexor (55 mg/m^2) | Selinexor (60 mg/m^2) | Selinexor (70 mg/m^2) | Selinexor (80 mg/m^2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Observed Concentration (Tmax) of Selinexor | NA (2.1 to 2.2) | 4.0 (2.1 to 7.7) | 3.0 (1.1 to 4.2) | 2.08 (0.92 to 8.5) | 2.0 (1.0 to 7.8) | 2.0 (0.72 to 4.4) | 2.0 (0.92 to 4.1) | 4.0 (2.0 to 7.5) | 2.0 (0.50 to 4.2) | 2.9 (1.0 to 8.0) | 1.9 (1.8 to 2.0) | 2.0 (1.0 to 4.0) | 2.0 (0.5 to 4.0) |
Cavg0-24h was defined as average concentration from time 0 to 24 hours.
| ng/mL | Selinexor (3 mg/m^2) | Selinexor (6 mg/m^2) | Selinexor (12 mg/m^2) | Selinexor (16.8 mg/m^2) | Selinexor (23 mg/m^2) | Selinexor (30 mg/m^2) | Selinexor (35 mg/m^2) | Selinexor (40 mg/m^2) | Selinexor (46 mg/m^2) | Selinexor (55 mg/m^2) | Selinexor (60 mg/m^2) | Selinexor (70 mg/m^2) | Selinexor (80 mg/m^2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Average Concentration From Time 0 to 24 Hours (Cavg0-24h) of Selinexor | 17.0 ± NA | 20.3 ± 94.8 | 61.8 ± 39.9 | 79.0 ± 61.8 | 108 ± 46.8 | 160 ± 38.0 | 168 ± 54.0 | 163 ± 29.2 | 297 ± 26.3 | 208 ± 19.1 | 337 ± 4.2 | 353 ± 26.2 | NA ± NA |
AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.
| nanogram* hours per milliliter | Selinexor (3 mg/m^2) | Selinexor (6 mg/m^2) | Selinexor (12 mg/m^2) | Selinexor (16.8 mg/m^2) | Selinexor (23 mg/m^2) | Selinexor (30 mg/m^2) | Selinexor (35 mg/m^2) | Selinexor (40 mg/m^2) | Selinexor (46 mg/m^2) | Selinexor (55 mg/m^2) | Selinexor (60 mg/m^2) | Selinexor (70 mg/m^2) | Selinexor (80 mg/m^2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 to t (AUC0-t) of Selinexor | 331 ± NA | 564 ± 41.9 | 1459 ± 20.5 | 1829 ± 23.3 | 2774 ± 36.7 | 3461 ± 26.9 | 3901 ± 29.2 | 4481 ± 23.8 | 5228 ± 21.6 | 5601 ± 36.2 | 5282 ± 57.9 | 5466 ± 45.7 | 5544 ± 33.2 |
AUC0-inf was defined as the area under the concentration-time curve from time zero to infinity (extrapolated).
| ng*h/mL | Selinexor (3 mg/m^2) | Selinexor (6 mg/m^2) | Selinexor (12 mg/m^2) | Selinexor (16.8 mg/m^2) | Selinexor (23 mg/m^2) | Selinexor (30 mg/m^2) | Selinexor (35 mg/m^2) | Selinexor (40 mg/m^2) | Selinexor (46 mg/m^2) | Selinexor (55 mg/m^2) | Selinexor (60 mg/m^2) | Selinexor (70 mg/m^2) | Selinexor (80 mg/m^2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selinexor | 348 ± NA | 733 ± NA | 1529 ± 18.7 | 1867 ± 23.6 | 2645 ± 1111 | 3513 ± 26.0 | 3948 ± 28.6 | 4552 ± 23.7 | 5284 ± 21.0 | 6089 ± 32.3 | 6964 ± 12.2 | 7803 ± 8.5 | NA ± NA |
Apparent volume of distribution was calculated as Dose/ (kel \*AUC0-inf), uncorrected for fraction absorbed, reported normalized by participant body weight (kilogram \[kg\]).
| Liter per kilogram (L/kg) | Selinexor (3 mg/m^2) | Selinexor (6 mg/m^2) | Selinexor (12 mg/m^2) | Selinexor (16.8 mg/m^2) | Selinexor (23 mg/m^2) | Selinexor (30 mg/m^2) | Selinexor (35 mg/m^2) | Selinexor (40 mg/m^2) | Selinexor (46 mg/m^2) | Selinexor (55 mg/m^2) | Selinexor (60 mg/m^2) | Selinexor (70 mg/m^2) | Selinexor (80 mg/m^2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution Uncorrected for Fraction Absorbed (Vd/F) of Selinexor | 1.6 ± NA | 1.5 ± NA | 1.9 ± 21.2 | 1.9 ± 29.9 | 1.9 ± 34.1 | 1.7 ± 24.1 | 2.0 ± 30.3 | 1.7 ± 29.1 | 1.8 ± 12.9 | 1.9 ± 27.9 | 1.6 ± 23.0 | 1.7 ± 13.4 | NA ± NA |
Cl/F was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed, reported normalized by participant body weight (kg).
| Liter per hour per kilogram (L/h/kg) | Selinexor (3 mg/m^2) | Selinexor (6 mg/m^2) | Selinexor (12 mg/m^2) | Selinexor (16.8 mg/m^2) | Selinexor (23 mg/m^2) | Selinexor (30 mg/m^2) | Selinexor (35 mg/m^2) | Selinexor (40 mg/m^2) | Selinexor (46 mg/m^2) | Selinexor (55 mg/m^2) | Selinexor (60 mg/m^2) | Selinexor (70 mg/m^2) | Selinexor (80 mg/m^2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Total Body Clearance, Uncorrected for Fraction Absorbed (Cl/F) of Selinexor | 0.19 ± NA | 0.21 ± NA | 0.21 ± 26.6 | 0.22 ± 22.8 | 0.20 ± 54.9 | 0.21 ± 25.3 | 0.22 ± 25.9 | 0.23 ± 26.2 | 0.22 ± 12.9 | 0.20 ± 24.6 | 0.19 ± 27.5 | 0.22 ± 7.8 | NA ± NA |
t½ was, calculated as ln(2)/kel, where kel is elimination rate constant, calculated using linear regression on the terminal portion of the log-linear concentration versus time curve.
| hour | Selinexor (3 mg/m^2) | Selinexor (6 mg/m^2) | Selinexor (12 mg/m^2) | Selinexor (16.8 mg/m^2) | Selinexor (23 mg/m^2) | Selinexor (30 mg/m^2) | Selinexor (35 mg/m^2) | Selinexor (40 mg/m^2) | Selinexor (46 mg/m^2) | Selinexor (55 mg/m^2) | Selinexor (60 mg/m^2) | Selinexor (70 mg/m^2) | Selinexor (80 mg/m^2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Terminal Half-Life (t½) of Selinexor | NA (5.5 to 6.1) | NA (4.4 to 5.1) | 6.2 (4.2 to 7.8) | 6.1 (3.1 to 8.7) | 6.9 (3.5 to 12.0) | 5.8 (3.9 to 8.4) | 6.2 (4.6 to 10.4) | 4.8 (2.7 to 9.8) | 5.7 (4.1 to 6.8) | 6.6 (5.4 to 10.1) | 5.9 (4.3 to 5.9) | 5.2 (5.0 to 6.0) | NA (5.5 to 5.5) |
Objective response for each malignancy was defined using the disease response criteria by malignancy; For NHL (including DLBCL, PTCL, and CTCL), objective response included complete response (CR) and partial response (PR). For MM, objective response included stringent complete response (sCR), CR, very good partial response (VGPR), and PR. For WM, objective response included CR, VGPR, and PR. For CLL, ALL, and AML, objective response included complete remission and Partial remission. For CML, objective response includes complete cytogenic response, and complete hematologic response (CHR).
| participants | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| Complete response | 5 | 1 | 0 | 0 | 0 |
| Partial response | 7 | 8 | 6 | 0 | 0 |
| Morphologic complete remission | 0 | 0 | 0 | 4 | 0 |
| Partial remission | 0 | 0 | 0 | 3 | 1 |
| Complete cytogenetic response | 0 | 0 | 0 | 0 | 0 |
| Complete hematological response | 0 | 0 | 0 | 0 | 0 |
Duration of response was defined as the time from the first occurrence of objective response to first documented evidence of disease recurrence or progression. Participants without evidence of progression were censored at time of last evaluable disease assessment. Objective response was defined as any response of partial response/remission or better for all malignancies; for AML, a response of morphologic leukemia-free state is also included for ORR. Duration of response was calculated by Kaplan-Meier method.
| Days | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| Duration of Response | 335.5 (48 to NA) | 251 (36 to NA) | 180 (57 to NA) | 76 (29 to NA) | NA (NA to NA) |
Progression-free survival (PFS) was calculated from the date of first dose of study drug to first documented evidence of disease recurrence or progression or death due to any cause. Participants who were last known to be alive and without evidence of progression were censored at time of last evaluable disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, participants were censored at the time of last evaluable disease assessment prior to the missed assessment.
| Days | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| Progression-free Survival | 47 (31 to 56) | 110 (28 to 274) | 57 (36 to 88) | 44 (36 to 52) | 57 (24 to 222) |
Duration of at least stable disease was defined as the time from the date of first dose of study drug to first documented evidence of disease recurrence or progression. Participants without evidence of progression were censored at time of last evaluable disease assessment.
| Days | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| Duration of at Least Stable Disease | 52 (32 to 79) | 114 (43 to 415) | 57 (43 to 100) | 80 (52 to 101) | 64 (21 to 283) |
Overall Survival was calculated from the date of first dose of study drug to date of death due to any cause. Participants who were last known to be alive were censored at time of last contact. Overall survival was calculated by Kaplan-Meier method.
| Days | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| Overall Survival | 138 (85 to NA) | 423 (423 to NA) | 366 (126 to NA) | 76 (48 to 114) | 82 (50 to NA) |
Collected over From first dose of study drug administration to end of treatment (up to 27 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diffuse Large B-cell Lymphoma (DLBCL) | — | 33/58 (56.9%) | 58/58 (100%) |
| Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | — | 7/27 (25.9%) | 27/27 (100%) |
| Multiple Myeloma (MM) | — | 52/81 (64.2%) | 80/81 (98.8%) |
| Acute Myeloid Leukemia (AML) | — | 73/95 (76.8%) | 94/95 (98.9%) |
| Other Hematological Malignancies (ALL, CML and CLL) | — | 13/24 (54.2%) | 24/24 (100%) |
| Event | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| SepsisInfections and infestations | 3/58 | 1/27 | 2/81 | 14/95 | 0/24 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/58 | 1/27 | 6/81 | 12/95 | 0/24 |
| PneumoniaInfections and infestations | 2/58 | 0/27 | 8/81 | 10/95 | 2/24 |
| Lung infectionInfections and infestations | 2/58 | 1/27 | 1/81 | 4/95 | 2/24 |
| FatigueGeneral disorders | 0/58 | 0/27 | 1/81 | 6/95 | 0/24 |
| PyrexiaGeneral disorders | 3/58 | 0/27 | 5/81 | 1/95 | 0/24 |
| DehydrationMetabolism and nutrition disorders | 2/58 | 0/27 | 3/81 | 5/95 | 0/24 |
| Confusional stateGeneral disorders | 3/58 | 0/27 | 1/81 | 0/95 | 0/24 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/58 | 0/27 | 4/81 | 2/95 | 0/24 |
| Acute kidney injuryRenal and urinary disorders | 1/58 | 0/27 | 4/81 | 1/95 | 0/24 |
| Event | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 38/58 | 18/27 | 64/81 | 55/95 | 18/24 |
| FatigueGeneral disorders | 39/58 | 13/27 | 62/81 | 67/95 | 16/24 |
| ThrombocytopeniaBlood and lymphatic system disorders | 39/58 | 15/27 | 52/81 | 47/95 | 17/24 |
| AnaemiaBlood and lymphatic system disorders | 34/58 | 14/27 | 42/81 | 46/95 | 16/24 |
| Decreased appetiteMetabolism and nutrition disorders | 34/58 | 16/27 | 54/81 | 62/95 | 13/24 |
| VomitingGastrointestinal disorders | 25/58 | 11/27 | 40/81 | 39/95 | 9/24 |
| DiarrhoeaGastrointestinal disorders | 24/58 | 9/27 | 32/81 | 46/95 | 10/24 |
| HyponatraemiaMetabolism and nutrition disorders | 25/58 | 7/27 | 36/81 | 34/95 | 11/24 |
| NeutropeniaBlood and lymphatic system disorders | 23/58 | 12/27 | 31/81 | 23/95 | 10/24 |
| Weight decreasedInvestigations | 14/58 | 10/27 | 32/81 | 31/95 | 3/24 |
Safety population consisted of all participants who received at least 1 dose of selinexor.
| Age, Continuous(years) | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) | Total |
|---|---|---|---|---|---|---|
| Mean | 57.8 ± 14.00 | 58.0 ± 15.90 | 62.1 ± 8.76 | 65.6 ± 15.33 | 60.9 ± 15.23 | 61.9 ± 13.79 |
| Sex: Female, Male(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) | Total |
|---|---|---|---|---|---|---|
| Female | 28 | 9 | 38 | 40 | 8 | 123 |
| Male | 30 | 18 | 43 | 55 | 16 | 162 |
| Ethnicity (NIH/OMB)(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 4 | 2 | 0 | 9 |
| Not Hispanic or Latino | 52 | 23 | 72 | 88 | 23 | 258 |
| Unknown or Not Reported | 4 | 3 | 5 | 5 | 1 | 18 |
| Race/Ethnicity, Customized(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Non-Hodgkin Lymphoma (NHL) Excluding DLBCL | Multiple Myeloma (MM) | Acute Myeloid Leukemia (AML) | Other Hematological Malignancies (ALL, CML and CLL) | Total |
|---|---|---|---|---|---|---|
| White | 52 | 20 | 65 | 88 | 23 | 248 |
| Black | 2 | 3 | 11 | 5 | 1 | 22 |
| Asian | 0 | 1 | 4 | 1 | 1 | 7 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaskan Native | 0 | 1 | 0 | 0 | 0 | 1 |
| Other | 0 | 2 | 1 | 0 | 0 | 3 |
| Unknown/Not Reported | 4 | 0 | 0 | 1 | 0 | 5 |
Plan to share: Yes
Ran from Jul 2012 to primary completion in Oct 2015, 38 months.
Results were first posted in Apr 2021, 5 years 5 months after primary completion.
Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's 38 months is below that.
Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor